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Background: Initiating antiretroviral therapy (ART) early during tuberculosis (TB) treatment increases
survival; however, implementation is suboptimal. Implementation science studies are needed to identify
interventions to address this evidence-to-program gap.
Objective: The Start TB Patients on ART and Retain on Treatment (START) Study is a mixed-methods,
cluster-randomized trial aimed at evaluating the effectiveness, cost-effectiveness, and acceptability of a
combination intervention package (CIP) to improve early ART initiation, retention, and TB treatment
success among TB/HIV patients in Berea District, Lesotho.
Design: Twelve health facilities were randomized to receive the CIP or standard of care after stratification by
facility type (hospital or health center). The CIP includes nurse training and mentorship, using a clinical
algorithm; transport reimbursement and health education by village health workers (VHW) for patients and
treatment supporters; and adherence support using text messaging and VHW. Routine data were abstracted
for all newly registered TB/HIV patients; anticipated sample size was 1,200 individuals. A measurement
cohort of TB/HIV patients initiating ART was recruited; the target enrollment was 384 individuals, each to be
followed for the duration of TB treatment (69 months). Inclusion criteria were HIV-infected; on TB
treatment; initiated ART within 2 months of TB treatment initiation; age ]18; English- or Sesotho-speaking;
and capable of informed consent. The exclusion criterion was multidrug-resistant TB. Three groups of key
informants were recruited from intervention clinics: early ART initiators; non/late ART initiators; and health
care workers. Primary outcomes include ART initiation, retention, and TB treatment success. Secondary
outcomes include time to ART initiation, adherence, change in CD4 count, sputum smear conversion, cost-
effectiveness, and acceptability. Follow-up and data abstraction are complete.
Discussion: The START Study evaluates a CIP targeting barriers to early ART implementation among
TB/HIV patients. If the CIP is found effective and acceptable, this study has the potential to inform care for
TB/HIV patients in high-burden, resource-limited countries in sub-Saharan Africa.
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Introduction
Despite the global scale-up of antiretroviral therapy
(ART), tuberculosis (TB) remains a significant cause of
morbidity and mortality among people living with HIV
(PLHIV). In 2014, approximately 1.2 million new TB
cases globally were HIV co-infected; 74% were in Africa
(1). TB is responsible for one quarter of deaths among
PLHIV (1). TB case fatality rates are 1635% in PLHIV in
the absence of ART, compared with 49% in HIV-negative
individuals (2). ART substantially reduces mortality risk
by 6495%, and is associated with a reduction in recurrent
TB (35). Three clinical trials demonstrated that initiating
ART early during TB treatment (within 24 weeks) greatly
increases AIDS-free survival by 3468% among indivi-
duals with advanced HIV disease (68), and World Health
Organization (WHO) guidelines recommend ART initia-
tion for all PLHIV as soon as possible after TB treatment
initiation, regardless of CD4 count (9).
Despite this compelling scientific evidence and strong
endorsement by the WHO, data from high-burden,
resource-limited countries suggest that when ART is pro-
vided to HIV-infected TB patients in programmatic
settings, uptake is suboptimal, and few co-infected patients
initiate ART within the recommended timeframe (1015).
Furthermore, retention in ART programs has been limited
(16).
Although studies have described various interventions
to address this evidence-to-program gap (10, 17, 18), few
have rigorously assessed a combination approach that
includes programmatic, structural, and psychosocial
interventions that target the various barriers commonly
described in the literature (15, 17, 1923). In addition,
there is a need for implementation science research that
not only evaluates the effectiveness and cost-effectiveness
of combination approaches, but also provides informa-
tion on the acceptability of the interventions from both
the patient and provider perspectives, as well as prag-
matic information on the implementation process (24).
Lesotho is a landlocked country surrounded by South
Africa with the world’s highest TB incidence (852 per
100,000) (1) and the second highest HIV prevalence
(23%) (25); 72% of TB patients are co-infected with HIV
(1). The Government of Lesotho has made admirable
strides in addressing the dual epidemics. At the time of
study start in 2012, 88% of TB patients had a known HIV
status and 97% of those diagnosed with HIV were placed
on cotrimoxazole prophylaxis; however, the rates of ART
initiation and retention during TB treatment remained
suboptimal (26).
We describe the design of the Start TB Patients
on ART and Retain on Treatment (START) Study,
a mixed-methods, cluster-randomized implementation
science study that aims to evaluate the effectiveness, cost-
effectiveness, and acceptability of a combination interven-
tion package (CIP) designed to improve early ART
initiation and retention during TB treatment, as well as
TB treatment success, among HIV-infected TB patients in
Lesotho.
Methods/design
The START Study is a two-arm, mixed-methods, cluster-
randomized trial. Twelve health facilities with integrated
TB/HIV clinics (the clusters) were randomized to deliver
a CIP or standard of care (SOC), following stratification
by facility type (hospital or health center).
Study setting
The study was conducted in Berea District of the King-
dom of Lesotho, a lower middle income sub-Saharan
African country of 2.1 million people (27). In 2014, 9,856
cases of all forms of TB were reported. The treatment
success rate for new and relapse TB cases registered in
2013 was 70%, short of the WHO’s 85% target (1).
The majority of people in Lesotho receive health care
at health centers staffed by nurses, who provide out-
patient care and preventive services. Complicated cases
are referred to district hospitals. Nurses can initiate TB
treatment for smear positive cases at the health center
level; smear negative cases are referred to the hospital for
evaluation and treatment initiation by a medical officer.
At the health center level, TB/HIV services including
provider-initiated HIV testing and counseling and the
provision of cotrimoxazole prophylaxis and ART are
well integrated with TB treatment and are provided as
one-stop services. At the hospital level, ART is integrated
within TB clinics, as per national guidelines. Typically,
each clinic providing TB/HIV services is staffed by one
to three nurses, plus one or two lay counselors, supported
by 2030 village health workers (VHW). TB treatment,
ART, and cotrimoxazole are dispensed on-site. Sputum
smear microscopy is available through specimen trans-
port to district hospitals by motorbike on a weekly basis.
Policy context and collaboration with the
Government of Lesotho
The Ministry of Health (MOH) National Tuberculosis
Program was engaged from the study conception and
design stage, when applying for funding. This participa-
tory approach (28) was adopted to ensure that the study
objectives were aligned with MOH priorities for control-
ling the TB/HIV epidemic. The MOH is represented
among the investigative team as well as the Stakeholder
Advisory Committee. By engaging the MOH and other
key stakeholders early and often in the planning and
implementation of the study, we aimed to foster country
ownership and maximize the impact of the study’s findings
on policy and programming.
Facility selection
Twelve of 17 public health facilities in Berea District
were selected for participation. The remaining five health
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facilities were excluded from the sampling frame because
patient volume was very low (on average, fewer than six
TB patients notified per quarter). Both hospitals (N2)
and health centers (N10) were included to enhance
generalizability. A single district was chosen in collabora-
tion with MOH to enhance internal validity by ensuring
comparability of health facilities randomized to either
study arm, and maximize cost efficiency.
Assignment to study arm
Assignment to a study arm was done at the health facility
level as opposed to the individual participant level. Health
facilities were stratified by facility type (i.e. hospital or
health center), and then numbered sequentially within
each stratum. Intervention status was randomly assigned
within each stratum by an investigator using SAS v. 9.3
(SAS Institute, Cary, NC). All HIV-infected TB patients
at facilities assigned to the SOC condition received
standard of care supported by the Lesotho MOH,
while all those enrolled in facilities assigned to the CIP
condition received the standard of care plus the interven-
tion package. Given the nature of the interventions,
participants, health care workers, and study staff were
not blinded to the assigned study arm.
Standard of care
At health facilities randomly assigned to SOC, the usual
procedures for the management of HIV-infected TB
patients were followed. Lay counselors offered HIV testing
to all TB patients, and integrated treatment for TB
and HIV is provided by nurses who are trained in the
National Guidelines for Tuberculosis (29). As per national
guidelines, HIV-infected TB patients are to be started
on ART 24 weeks after initiating TB treatment, regard-
less of CD4 count. There is no standardized, nationally
approved curriculum to provide patients with treatment
and adherence literacy.
Directly observed therapy for TB may be provided by
a nurse at the health facility, but is generally provided by
a treatment supporter, who is usually a family member.
Designation of a treatment supporter by the patient is
not verified by the nurse. Treatment supporters are not
required to accompany patients to clinic visits, and thus
often do not receive any education on TB or adherence.
VHW are trained to be treatment supporters; however,
there is no formal referral system to ensure that patients
are linked with them. VHW are minimally supervised,
and they communicate infrequently with providers at
nearby health facilities.
TB patients return to the health facility monthly for
a 30-day supply of medications and monitoring of
side effects and adherence. The tracing of patients lost
to follow-up is usually attempted on a quarterly basis
but outreach activities are often limited owing to lack of
transportation and means of communication.
Combination intervention package
At health facilities randomly assigned to CIP, the
intervention was delivered to all TB/HIV patients during
regular clinic visits as part of routine care. All nurses and
VHW affiliated with the TB/HIV clinic were trained
to implement the CIP. CIP contained programmatic,
structural, and psychosocial components, including: 1)
nurse training and mentorship in TB/HIV co-treatment,
using a clinical algorithm; 2) reimbursement of trans-
portation costs to monthly clinic visits for patients and
treatment supporters; 3) health education for patients
and treatment supporters by VHW using a treatment
literacy curriculum; and 4) real-time adherence support
using short message service (SMS) text messaging
and trained VHW. Table 1 shows a comparison of the
study arms.
Programmatic components of CIP: nurse training and
mentorship in TB/HIV co-treatment, using a clinical
algorithm
All nurses working in CIP clinics participated in a 2-day
training on the scientific evidence and guidelines regard-





Training on national TB guidelines for nurses X X
ART provision to TB/HIV patients in integrated clinics X X
Patient-identified treatment supporter for TB treatment X X
Nurse training and mentorship in TB/HIV co-treatment using a clinical algorithm X
Reimbursement of transportation costs to monthly clinic visits for patients and
treatment supporters
X
Health education for patients and treatment supporters by village health workers
using TB/HIV treatment literacy curriculum
X
Real-time adherence support using automated SMS text messages and trained
village health workers
X
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ing treatment of TB/HIV co-infection, the importance of
early ART initiation during TB treatment to improve
survival, and use of a clinical algorithm to manage TB/
HIV patients. Job aids, such as laminated desk charts and
posters depicting the algorithm, were provided for each
consultation room to support intervention delivery.
Clinic nurses used the algorithm to initiate ART; monitor
for adherence, treatment response, and side effects; and
diagnose and manage adverse events, including immune
reconstitution inflammatory syndrome (IRIS). Nurses
explained to TB/HIV patients that ART can improve
survival, encouraged ART initiation, and referred pa-
tients to the facility-based lead village health worker
(LVHW) for further education. Nurses also delivered
specific adherence messages and assessed ART and TB
treatment adherence at follow-up visits, referring patients
to the LVHW for additional adherence counseling.
A nurse program monitor visited the clinics two to three
times per month to provide ongoing mentorship in
TB/HIV co-treatment to the clinic nurses and LVHW
and provided refresher training as needed.
Structural component of CIP: reimbursement of
transportation costs
TB/HIV patients initiating ART were asked to bring their
treatment supporter to their monthly clinic visits, so
that they could participate in education and counseling
sessions with the LVHW, and discuss any adherence
problems. Both patients and treatment supporters were
reimbursed for transportation costs in the amount of
15 loti (approximately 1.4 USD) after each clinic visit.
Psychosocial components of CIP
Psychosocial components of CIP were delivered by
VHW, whose role encompassed social support, system
navigation, referrals, and advocacy. VHW responsibi-
lities included providing information; communicating
with patients; encouraging ART initiation, adherence to
ART and TB treatment, and retention in care; offering
support and empathy; providing referrals; and advocating
for patients. In order to improve VHW oversight and
coordination, one to two VHW were assigned to be LVHW
at each facility, according to patient volume. LVHW were
chosen by a joint committee of their peers and the nurse
in charge, and received a monthly stipend of 750 loti
(approximately 70.0 USD). All VHW completed a 4-day
training in both didactic learning and interactive techni-
ques, including case studies and role-playing to develop
skills. LVHW completed an additional 2 days of training
on their additional responsibilities at the health facility,
as well as their role supervising VHW in the community.
LVHW assigned new TB/HIV patients initiating ART
to a community-based VHW, who provided adherence
support between clinic visits. VHW conducted home visits
and contacted patients by phone, weekly for the duration
of TB treatment, to discuss adherence and side effects.
They also followed up with patients who missed clinic
appointments, contacting the LVHW or nurse for gui-
dance when necessary, and linked patients with commu-
nity-based services as needed. VHW were provided with
airtime vouchers (40 loti, approximately 3.7 USD) each
month.
LVHW used a TB/HIV treatment literacy curriculum
to provide group health education sessions at the health
facility. They also met individually with TB/HIV patients
and their treatment supporters to provide ART prepara-
tion and adherence counseling for the duration of their
TB treatment. A scripted, illustrated flipchart was devel-
oped for LVHW. It provides information on the natural
history of HIV, importance of early ART initiation,
use of TB and antiretroviral medications, common side
effects, and the importance of adherence. In response to
an expressed need from LVHW, a second flipchart that
provides information on and support for HIV disclosure
was also developed.
In addition, LVHW enrolled TB/HIV patients initiating
ART and their treatment supporters in an automated text
messaging system supported by Dimagi Commcare (www.
dimagi.com/), using a customized mobile phone applica-
tion. This system sent text messages in Sesotho, including
medication adherence messages and appointment remin-
ders. Adherence messages used code words (Did you eat
your meal today?) to protect patients’ confidentiality.
They were sent on a daily basis during the first month of
ART, then on a patient-specified schedule (daily or
weekly) for the remainder of TB treatment. Appointment
reminders were sent 2 and 1 day prior to each clinic visit.
The time of day for all messages was chosen by the
recipient. LVHW described text messaging in detail and
practiced receiving text messages with patients and
treatment supporters until they felt comfortable with the
technology. LVHW also dispensed airtime vouchers (40
loti, approximately 3.7 USD) to patients and treatment
supporters at their monthly clinic visits, so that they were
able to communicate with their VHW or nurse in case of
difficulties.
In addition, LVHW managed the clinic appointment
system, including scheduling appointments, checking
the appointment book to confirm attendance, and notify-
ing the assigned VHW if any patients missed their
appointments. They escorted patients to other services
at the health facility when needed. They also supervised
the VHW in the community on a weekly basis using a
standardized checklist, and held monthly meetings with
the VHW and clinic nurses at the health facility to discuss
patient challenges.
Study participants
The different groups of study participants are shown in
Fig. 1.
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All newly registered TB/HIV patients
Routinely collected data were abstracted for all TB/HIV
patients newly registered for TB treatment at the 12 study
clinics during the first 24 months of observation.
Measurement cohort
In addition, a measurement cohort of TB/HIV patients
initiating ART was recruited. Inclusion criteria were 1)
HIV-infected; 2) on TB treatment; 3) initiated ART
within 2 months of TB treatment initiation; 4) aged
18 or older; 5) English- or Sesotho-speaking; and 6)
capable of and willing to provide informed consent within
3 working days of ART initiation. Patients with multi-
drug-resistant TB were excluded from the measurement
cohort.
Key informants
Three groups of key informants were recruited from CIP
clinics: 1) ART early initiators; 2) ART non/late initia-
tors; and 3) health care workers.
The inclusion criteria for ART early initiators were
1) measurement cohort participation at a CIP clinic; and
2) ART initiation at minimum 2 weeks prior to comple-
tion of key informant interview.
Inclusion criteria for ART non/late initiators were
1) HIV-infected; 2) recently completed TB treatment at
CIP clinic (if non-initiator) or on TB treatment for 2
months or longer (if late initiator); 3) ART-naı¨ve or ART
initiated 2 months or longer after TB treatment initiation;
4) aged 18 or older; 5) English- or Sesotho-speaking; and
6) capable of and willing to provide informed consent.
Patients with multidrug-resistant TB were excluded.
Initially, we aimed to recruit ART non-initiators only;
however, inclusion criteria were broadened to include
late initiators in month 7 of key informant recruitment,
as sufficient numbers of TB/HIV patients who were ART-
naı¨ve could not be identified.
Inclusion criteria for health care workers were 1) nurse
or VHW working in a CIP clinic or VHW working in
the community and affiliated with CIP clinic; 2) aged 18
or older; 3) English- or Sesotho-speaking; and 4) capable
of and willing to provide informed consent. Nurses and




Nurses were asked to inform TB/HIV patients initiating
ART about the study and to refer them to the research
assistant (RA) if they were interested in obtaining
more information. To achieve steady enrollment across
study arms, a monthly enrollment quota was set for
each site and, consecutively, eligible consenting patients
were enrolled until the target number of participants was
reached.
Key informants
ART early initiators were recruited from the measurement
cohort, so that monthly questionnaire data could be used
to characterize them. Heterogeneous purposive sampling
was utilized (30, 31), according to the following recruit-
ment targets: 1) equal numbers of men and women;
2) equal numbers of participants aged 1835 years and
older; and 3) a proportional number of participants at
each CIP clinic, based on patient intake. ART non/late
initiators were referred to the RA by clinic nurses.
Convenience sampling was utilized (30), according to the
following recruitment targets: 1) equal numbers of men
and women; and 2) a proportional number of participants
at each CIP clinic, based on patient intake. Health care
workers were referred to the RA by the nurse in charge.
Convenience sampling was utilized, with the following
recruitment targets: 1) at least one nurse per clinic; 2) at
least one LVHW per clinic; and 3) at least one community-
based VHW per clinic.
For all participant groups, RA met with potential parti-
cipants in a private area to provide further information
Fig. 1. Study Participants. All newly registered TB/HIV
patients at study sites in both conditions are represented by
the large circle; those who initiated ART during the first 2
months of TB treatment (ART early initiators) are depicted in
blue, while those who did not initiate ART or initiated ART
after the first 2 months of TB treatment (ART non/late
initiators) are depicted in green. A sample of ART early
initiators from study sites in both conditions who enrolled in
the measurement cohort are represented by the yellow circle.
Key informants at CIP study sites included: 1) ART early
initiators (I KI), depicted by the white circle; 2) ART non/late
initiators (NI KI), depicted by the pink circle; and 3) health
care workers (HCW KI), depicted by the orange circle.
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about the study using a standardized script, assess
eligibility, and obtain written informed consent.
Data collection
All newly registered TB/HIV patients
RA abstracted demographic, clinical, and laboratory
data from the clinic TB and ART registers and patient
TB treatment and HIV care cards using a standardized
tool. Standardized data quality assurance procedures
were implemented at all study sites to mitigate the amount
of missing data abstracted from clinic records. Patient
information was recorded in disparate paper and electro-
nic systems that were not always incorporated into the
patient files. Study staff conducted regular reviews of
patient files, various clinic registers, laboratory informa-
tion systems, and other source documents to ensure a high
standard of completeness of the key study variables.
Measurement cohort
Consenting participants in both conditions completed
the same standardized assessments, including interviewer-
administered questionnaires at baseline and monthly
follow-up visits coinciding with their clinic visits and
monthly phone-based unannounced pill counts, for the
duration of TB treatment (69 months). All interviews
were conducted in either Sesotho or English, based on
participant preference. In addition, RA abstracted detailed
information from clinic records on participants’ clinic
visits and medication refills.
Interviewer-administered questionnaires. The baseline
questionnaire included measures of sociodemographic
characteristics (32), patient costs, disclosure of HIV status,
HIV- and TB-related knowledge and attitudes, depression
(PHQ-9) (33), alcohol dependence (AUDIT) (34), barriers
to medical care, social support, health literacy, social
desirability (35), and side effects. The follow-up question-
naire included measures of self-reported 30-day adherence
(36), side effects, and patient costs. The end-of-treatment
questionnaire included the same measures included in the
baseline and follow-up questionnaires, as well as measures
of utilization and acceptability of services.
Unannounced pill counts. Participants were called on their
mobile phone at an undisclosed time between their
monthly study visits and asked to count the pills remain-
ing in their pill bottles or plastic envelopes (37).
Key informants
In-depth qualitative interviews were conducted with con-
senting key informants using semi-structured interview
guides (38) that were tailored for each key informant
group. Interviews were audio recorded, transcribed verba-
tim, and translated from Sesotho to English. Acceptability,
preferences, and utilization of intervention components
were explored among ART initiators. Reasons for the
lack of or late initiation of ART were explored among
ART non/late initiators. Experiences delivering the inter-
vention, perceived barriers and facilitators, perceptions
about acceptability, and the ease of uptake and delivery of
the intervention components were explored among health
care workers.
Cost drivers
RA administered cost surveys to nurses and VHW on a
monthly basis to capture the program costs associated
with CIP implementation.
Process documentation
Several instruments were also completed by study staff to
document the implementation process. A brief semi-
structured Program Characteristics Survey was adminis-
tered by the RA to the nurse in charge at each clinic in
both study conditions, prior to study implementation,
and on a monthly basis thereafter. The survey tracked the
implementation of intervention components to assess
fidelity, potential contamination, as well as system-level
factors that may impact CIP implementation. At each
CIP site, the RA also completed an intervention receipt
log for mobile airtime, SMS messages, and transportation
reimbursement to document the dosage of intervention
components received by each patient, and the program
monitor completed a supervision checklist during each
mentorship visit to assess intervention quality (39).
Copies of data collection instruments are available
from the corresponding author upon request.
Data management
Data for participant interviews and chart abstractions
were collected on paper-based forms. Completed forms
were stored in a locked filing cabinet at each clinic site,
and on a weekly basis were transported in a locked box
to a field study office for entry in the study database.
The database was encrypted, password-protected, and
contained established quality control measures, including
skip patterns, range limitations, and consistency checks
to enhance the accuracy and completeness of the data
collected. The database was backed up nightly to an
encrypted external hard drive maintained in a locked
filing cabinet.
Throughout the study, four levels of review were
conducted to ensure the completeness and accuracy of
the study data. First, the study coordinator conducted
random checks of 10% of the completed study forms for
errors and completeness. Second, the data manager con-
ducted a random verification of 10% of the records newly
entered into the study database against the paper data
collection forms. Third, during external monitoring visits,
the project coordinator reviewed 10% of the data collection
forms entered into the study database for completeness
and accuracy, comparing data collection forms with source
documentation and hardcopy forms with the study data-
base. In addition, the data analyst ran code to check for
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missing data and inconsistencies and flagged problematic
observations for the study team to verify against paper-
based study forms or with source documentation at the
study site.
Primary and secondary endpoints
Primary outcomes include: 1) ART initiation, 2) ART
retention, and 3) TB treatment success. Secondary
outcomes include: 1) time to ART initiation, 2) ART
adherence, 3) change in CD4 count, 4) sputum smear
conversion, 5) TB treatment adherence, 6) cost-effectiveness,
and 7) acceptability. All outcomes pertain to the individual
participant level. ART initiation is defined as the percentage
of TB/HIV patients newly registered during the period of
observation who initiated ART during TB treatment, based
on review of clinic records. ART retention is defined as
the percentage of measurement cohort participants who
attended their 6-month clinic visit (within a 1-month
window) and reported ART use. Deaths and transfers will
be considered not retained. TB treatment success is defined as
the percentage of TB/HIV patients whose TB treatment
outcome is documented in the TB register or treatment card
as treatment completion or cure, as defined by the WHO (40).
Time to ART initiation will be expressed as the number of
days from TB treatment initiation to ART initiation.
Adherence is determined separately for ART and TB
treatment and defined by the percentage of total prescribed
doses ingested, averaged across medicines for each month of
treatment, from the unannounced pill counts. Change in
CD4 count is defined as the difference in CD4 count 6
months after TB treatment initiation. Sputum smear con-
version is defined as the percentage of smear positive
pulmonary TB cases that converted to smear negative after
8 weeks of treatment (40). Incremental cost-effectiveness will
be estimated as the ratio of the incremental costs of the CIP
per ART initiation, retention, and TB treatment success.
Acceptability of intervention components will be character-
ized via in-depth qualitative analysis and interpretation
(41). Table 2 lists the study outcomes for each group of
participants.
Sample size and power calculations
Power calculations for all TB/HIV patientswere based on our
primary outcomes ART initiation and TB treatment success.
Based on previous programmatic data, we anticipated an
average of 100 newly registered TB/HIV patients at each
of the 12 study clinics over the first 24 months
of observation. When the study was designed, available
data demonstrated that only 27% of HIV-infected TB
patients in Lesotho had received ART, and the TB treatment
success rate was 70% for new smear positive cases, 64% for
new smear negative and extrapulmonary cases, and 62% for
retreatment cases (HIV-positive and HIV-negative cases
combined) (42). Assuming a two-sided Farrington & Man-
ning Likelihood Score Test with a0.05 and an intra-cluster
correlation coefficient (ICC) of 0.05, we will have 83% power
to detect a difference in ART initiation from 40% (SOC) to
60% (CIP), and 91% power to detect a difference in TB
treatment success from 65% (SOC) to 85% (CIP) (PASS 2008,
NCSS Statistic Software). As per standard practice, patients
who die or are lost to follow-up before ART initiation or TB
treatment completion are considered to have not initiated
ART or to have not achieved TB treatment success,
respectively, and thus power calculations for these outcomes
do not include an allowance for attrition.
Power calculations for measurement cohort partici-
pants were based on our primary outcome ART retention.
Assuming 100 TB/HIV patients in each of the 12 study
clinics, 40% ART initiation at SOC clinics, and at least
80% study enrollment, we aimed to enroll 384 participants
(32 per clinic) initiating ART in the measurement cohort.
Assuming a two-sided Farrington & Manning Likelihood
















TB treatment successa X
Time to ART initiation X
ART adherence X
Change in CD4 count X
TB treatment adherence X
Sputum smear conversion X
Incremental cost-effectiveness X
Acceptability of intervention components X X X
Reasons for ART non/late initiation X
aPrimary outcomes.
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Score Test with a0.05 and ICC of 0.05, we will have
87% power to detect a difference in ART retention from
70% (SOC) to 90% (CIP).
Data analysis
An intent-to-treat analysis will be used. In addition, when
measuring adherence in the measurement cohort, an
as-treated analysis will be used to exclude participants
who died or discontinued medications due to adverse
events. Generalized linear mixed models (Proc Glimmix
procedures in SAS v9.3 with a random intercept for study
site) will be applied to test for a difference between study
arms for dichotomous (ART initiation, ART retention,
TB treatment success, sputum smear conversion) and
continuous (ART adherence, change in CD4 count,
TB treatment adherence) outcomes; frailty models (Proc
Phreg procedures in SAS v9.3 with random intercept
for study site) will be utilized for time to event analysis
(time to ART initiation) to account for the clustering
of characteristics that may occur among patients attend-
ing the same study site. These approaches will provide
appropriate adjustments to the standard errors account-
ing for potential non-independence of observations (43).
Models will include fixed effects for study condition,
patient characteristics, time-varying adherence measures
and CD4 count (for change in CD4 count) and
random effects for site. Participants who transferred to
another site before ART initiation will be censored, and
death before ART initiation will be treated as a compet-
ing risk.
For the cost-effectiveness analysis, a model will be
created to estimate the incremental cost of CIP relative to
SOC. The costs will be composed primarily of the variable
costs involved in training nurses and convening VHW,
but will also include the costs of administering SMS
messages and the fixed costs involved in administering
the intervention. The incremental cost-effectiveness of
CIP will be estimated as the ratio of the incremental costs
to incremental effectiveness with effectiveness measured in
terms of the study’s primary outcomes.
For analysis of acceptability of the CIP, two investiga-
tors will independently review the first five interviews from
each group of key informants to develop a preliminary
checklist of codes using a grounded theory framework
(41, 44). The individual checklists will be compared and
reconciled to create a coding dictionary, which will be used
by the study team to independently code each interview.
Additional codes will be added if they emerge in the
analysis of subsequent interviews. Codes will accordingly
serve as building blocks for qualitative concepts and
themes. Themes will be cross-checked to enhance inter-
rater reliability, and negative case analysis and critical
reflexivity will be used to strengthen analytic credibility
(41, 45). Data from patients and providers will be
analyzed separately and comparatively. Data analysis
will explore contextual factors related to the acceptability
of CIP components among patients; detect differences,
if any, between men and women; and will shed light
on common and divergent characteristics of patients’ and
providers’ barriers and facilitators.
Monitoring
As this is an implementation science study with minimal
risks, a data monitoring committee was not needed. Study
staff was trained to assess for adverse events and notify
the principal investigator immediately if they learned of an
adverse event. If there was an adverse event, an incident
report was to be completed describing the incident,
what caused it, and steps that would be taken to prevent
recurrence, and the Columbia University Medical Center
Institutional Review Board and the Lesotho National
Health Research and Ethics Committee were to be in-
formed according to their respective reporting guidelines.
Internal monitoring of each study site was performed by
the study coordinator on a monthly basis, to ensure that
each site was adhering to the study protocol and standard
operating procedures. External monitoring visits were
performed semi-annually by a US-based project coordi-
nator and included review of each site’s performance,
the completion and storage of data collection forms, data
entry, and adherence to confidentiality guidelines.
Ethics and consent process
The protocol and any modifications were reviewed and
approved by the Columbia University Medical Center
Institutional Review Board and the Lesotho National
Health Research and Ethics Committee. RA obtained
written informed consent from all measurement cohort
participants and key informants completing in-depth
interviews.
Consent forms and all of the identifying information
obtained at study enrollment to track participants were
stored in separate locked filing cabinets at study sites in a
locked room. Upon enrollment, each participant was
assigned a unique identification number. The study ques-
tionnaires, data abstraction forms, and databases included
participant unique identification numbers only; no parti-
cipant names or identifiers were recorded. A master list
with each participant’s name and unique identification
number is stored in a locked cabinet, and will be
maintained only long enough to permit the investigators
to review and audit the data, following which this
document will be destroyed. Investigators have and will
maintain access to the full trial dataset.
Dissemination
A dissemination strategy was developed to ensure that
study findings are shared with key stakeholders, regardless
of the magnitude or direction of effect. This strategy
includes a dissemination meeting in Lesotho with the
MOH, District Health Management Team, health care
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workers, and patients from participating health facilities;
a dissemination report for the MOH; presentations at
scientific conferences; and publications in peer-reviewed
journals. Investigators will adhere to recommendations
from the International Committee of Medical Journal
Editors regarding authorship. Data, from which all
identifiers have been removed, will be made publicly
available following the publication of primary and sec-
ondary outcome papers in accordance with Open Data
Policy of the United States Agency for International
Development (USAID) (46).
Trial status
The study commenced with the enrollment of measure-
ment cohort participants in April 2013 and the recruit-
ment of key informants in March 2014; the enrollment
of all participants was completed in March 2015 and
follow-up procedures including clinical and laboratory
record abstraction was completed in March 2016.
Discussion
The START Study aims to evaluate a CIP designed to
improve early ART initiation and retention during TB
treatment, as well as TB treatment success, among HIV-
infected TB patients in Lesotho. The study utilizes an
implementation science framework to not only assess the
effectiveness and cost-effectiveness of the combination
approach, but also provide information on the accept-
ability of the interventions from both the patient and
provider perspectives, as well as pragmatic information
on the implementation process. The study interventions
target known programmatic, structural, and psychosocial
barriers to early ART implementation in high-burden,
resource-limited settings, and were selected for their
promise, practicality, and feasibility of implementation
and scale-up in TB/HIV programs in diverse contexts.
The goal of this study is to improve health outcomes
among PLHIV in Lesotho, and generate generalizable
knowledge that could be applied to similar high-burden,
resource-limited settings.
We used a cluster-randomized design for a number of
reasons. First, the delivery of study interventions at the
health facility level is conducive to the study’s implemen-
tation science approach as it mimics the way in which
the CIP would be delivered outside of a study setting.
In addition, it was considered more feasible for the clinic
staff to provide all patients at the site with the same
intervention package, rather than deliver the CIP to some
patients and not others, which would be the case in an
individual-randomized design. Furthermore, though there
were no data to support that the CIP would be superior to
the SOC, individual randomization might have resulted in
some patients randomized to SOC feeling that they were
receiving substandard care, which in turn might have
influenced their engagement in care and, consequently, the
key study outcomes of ART initiation and retention.
Our study has several strengths. First, the cluster-
randomized approach permits the causal attribution of
observed outcomes to the CIP by comparing them to the
counterfactual scenario, while reducing selection bias (47).
Second, the use of mixed methods (48, 49), whereby the
collection and analysis of quantitative data is followed by
the utilization of qualitative research tools in a sequential
explanatory phase, will allow us to evaluate the accept-
ability and utilization of intervention components, and
collect reasons for the lack of or late initiation of ART in
TB/HIV patients. Third, the participatory approach, with
meaningful stakeholder engagement in both the design
and implementation phases, has fostered MOH ownership
at the national and district levels, and will help to ensure
the successful integration of study findings in policy and
programmatic contexts. In addition, we are testing an
innovative, multifaceted intervention that builds on the
evidence base of prior scientific work, while addressing
the diverse barriers to ART initiation and retention in
TB/HIV patients. Finally, the selected study sites have
adequate heterogeneity, covering facilities in both urban
and rural locations in low-land, foothill, and moun-
tainous areas, which will strengthen the external validity
of findings.
The limitations of the study design include the potential
for unanticipated health system inefficiencies to impact
CIP implementation, including interruptions in health
care worker availability, laboratory commodities, and
drug supplies. However, any changes in these elements
are likely to be similar across study arms and reflect
system dynamics captured in implementation science.
In addition, the reliance on routinely collected program-
matic data for some study outcomes means that data may
be incomplete for some study participants. Standardized
data quality assurance procedures implemented at all
study sites aim to mitigate the amount of missing data.
Furthermore, as the study is limited to one district,
there is the potential for contamination and migration,
which would result in a decrease in power to detect a
difference between study arms. However, given the goal of
assessing CIP effectiveness in a health systems context, it
is important to evaluate the impact in realistic program-
matic scenarios, while seeking to understand the findings
by monitoring spillover and crossover through process
documentation. Last, the study design precludes evalua-
tion of the effectiveness of individual components of the
CIP, which would require a considerably larger sample
size. However, qualitative results will highlight patient and
provider perspectives on the utility of various interven-
tion components, and process data will demonstrate
utilization of each study intervention.
ART uptake and retention during TB treatment
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Conclusions
The START Study aims to improve early ART initiation
and retention during TB treatment. Achieving this goal
will result in improved health outcomes among PLHIV
as well as reduced HIV and TB transmission in the
population. With one of the world’s most severe epidemics
of HIV and TB, Lesotho would benefit greatly from the
identification of an effective strategy to integrate this
life-saving treatment into TB service delivery programs.
If this study demonstrates that the CIP is effective,
cost-effective, and acceptable, these findings can be used
to advocate for its adoption as standard of care for HIV-
infected TB patients in other high-burden, resource-
limited countries in sub-Saharan Africa.
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Paper context
Initiating antiretroviral therapy early during tuberculosis
treatment increases the survival of HIV-infected tuberculosis
patients; however, implementation is suboptimal. The
START Study is a mixed-methods cluster-randomized trial
aimed at evaluating the effectiveness, cost-effectiveness, and
acceptability of a combination intervention package to
improve early antiretroviral therapy initiation, retention,
and tuberculosis treatment success among HIV-infected
tuberculosis patients in Lesotho. This study has the potential
to inform care for HIV-infected tuberculosis patients in high-
burden, resource-limited countries in sub-Saharan Africa.
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